Author

D. H. Barouch

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 23 Microbiology· 10 Biochemistry· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 28 Research Focus:host-pathogen & immune response· 27 Organism:human· 11 Organism:mouse· 11 Assay:proteomics· 9 Organism:rat· 9 Research Focus:drug response / drug discovery· 8 Organism:non-human primate· 7

Frequent Co-Authors

J. Yu· 13 shared A. Chandrashekar· 8 shared J. Liu· 8 shared K. McMahan· 8 shared H. Andersen· 6 shared A. Chang· 5 shared A. Cook· 5 shared A. J. Martinot· 5 shared

Activity by Year

2018-2024 · peak 15/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

13 shared papersImmunology

J. Yu

Mutual co-authors in cluster

Author profile →

35 papers

Recent·Most cited

Global variation in prior exposure shapes antibody neutralization profiles of SARS-CoV-2 variants up to BA.2.86

S. Turner, G. Amirthalingam, D. Bailey, D. H. Barouch, K. R. Bewley, K. Brown, Y. R. Cao, Y.-W. Chan, S. Charlton, DOVE consortium, N. S. Coombes, B. Hallis, D. D. Ho, F. Jian, N. Lasrado, , D. J. Smith

The paper analyzes antibody neutralization data from multiple countries to assess how prior exposure to SARS-CoV-2 variants affects neutralization profiles of BA.2.86 and its descendants.

bioRxiv · Mar 27, 2024 · PreprintImmunology

Compartment-Specific Antibody Correlates of Protection to SARS-CoV-2 Omicron in Macaques

X. Tong, Q. Wang, W. Jung, T. M. Chicz, R. Blanc, L. J. Parker, D. H. Barouch, R. P. McNamara

This study identifies compartment-specific antibody correlates of protection against SARS-CoV-2 Omicron in macaques, showing neutralizing antibodies in serum and antibody-dependent cellular phagocytosis in bronchiolar lavage are strongest correlates.

bioRxiv · Mar 1, 2024Immunology

Last in first out: SIV proviruses seeded later in infection are harbored in short-lived CD4+ T cells

N. Sambaturu, E. J. Fray, F. Wu, C. Zitzmann, F. R. Simonetti, D. H. Barouch, J. D. Siliciano, R. F. Siliciano, R. M. Ribeiro, A. S. Perelson, C. Molina-Paris, T. Leitner

The paper models SIV provirus divergence in CD4+ T cells, finding that short-lived cells harbor more diverged virus, while long-lived cells contain less diverged virus, explaining contradictory prior results on reservoir timing.

bioRxiv · Nov 3, 2023 · PreprintMicrobiology

Contrasting Effects of SARS-CoV-2 Vaccination vs. Infection on Antibody and TCR Repertoires

J. Braun, E. D. Hill, E. Contreras, M. Yasuda, A. Morgan, S. Ditelberg, E. Winter, C. Callahan, G. Mazzoni, A. Kirmaier, H. Mirebrahim, H. Asgharian, D. Telman, A.-R. Y. Collier, D. H. Barouch, , R. Arnaout

This study compares antibody and TCR repertoires in SARS-CoV-2 infectees, vaccinees, and controls to predict neutralizing antibody titers and identifies subtle differences in adaptive immune responses.

bioRxiv · Sep 8, 2023 · PreprintImmunology

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.2.86

N. Lasrado, A.-r. Collier, N. Hachmann, J. Miller, M. Rowe, E. Schonberg, S. Rodrigues, A. LaPiana, R. Patio, T. Anand, J. Fisher, C. Mazurek, R. Guan, K. Wagh, J. Theiler, , D. H. Barouch

This study evaluates the neutralization escape of the SARS-CoV-2 Omicron subvariant BA.2.86 compared to other variants, finding lower neutralization by antibodies than BA.2 but comparable to circulating variants.

bioRxiv · Sep 4, 2023Microbiology

Attenuated Mycobacterium tuberculosis Vaccine Protection in a Low Dose Murine Challenge Model

S. J. Vidal, D. Sellers, J. Yu, S. Wakabayashi, J. Sixsmith, M. Aid, J. Barrett, S. F. Stevens, X. Liu, W. Li, C. R. Plumlee, K. B. Urdahl, A. J. Martinot, D. H. Barouch

This study shows that the live attenuated Mtb vaccine candidate ΔLprG provides better protection than BCG in a low dose murine challenge model, reducing detectable infection and containing it anatomically.

bioRxiv · Mar 17, 2023 · PreprintMicrobiology

Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters

N. Lasrado, A.-r. Collier, J. Miller, N. Hachmann, J. Liu, M. Sciacca, C. Wu, T. Anand, E. Bondzie, J. Fisher, C. Mazurek, R. Patio, O. Powers, S. Rodrigues, M. Rowe, , D. H. Barouch

This study evaluates the durability of humoral and cellular immune responses to XBB.1.5 after bivalent mRNA boosters, finding waning neutralizing antibody titers but preserved T cell responses.

bioRxiv · Jan 22, 2023 · PreprintImmunology

Substantial Neutralization Escape by the SARS-CoV-2 Omicron Variant BQ.1.1

J. Miller, N. Hachmann, A.-r. Collier, N. Lasrado, C. Mazurek, R. Patio, O. Powers, N. Surve, J. Theiler, B. Korber, D. H. Barouch

The paper shows BQ.1.1 SARS-CoV-2 variant has greater neutralization escape compared to BA.5, with lower NAb titers in vaccinated individuals.

bioRxiv · Nov 1, 2022 · PreprintImmunology

Rapid Loss of CD4 T Cells by Pyroptosis During Acute SIV Infection in Rhesus Macaques

X. He, M. Aid, J. Ventura, E. Borducchi, M. A. Lifton, J. Liu, D. H. Barouch

This study identifies pyroptosis as the main cause of CD4 T cell loss in acute SIV infection in rhesus macaques, with IFI16 upregulation linked to viral loads and cell depletion.

bioRxiv · May 24, 2022Microbiology

Vaccine Protection Against the SARS-CoV-2 Omicron Variant in Macaques

A. Chandrashekar, J. Yu, K. McMahan, C. Jacob-Dolan, J. Liu, X. He, D. Hope, T. Anioke, J. Barrett, B. Chung, N. Hachmann, M. Lifton, J. Miller, O. Powers, M. Sciacca, , D. H. Barouch

This study evaluates vaccine efficacy against SARS-CoV-2 Omicron in macaques, finding that both humoral and cellular immune responses are necessary for virologic control.

bioRxiv · Feb 6, 2022Microbiology

Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters

K. McMahan, V. Giffin, L. Tostanoski, B. Chung, M. Siamatu, M. Suthar, P. Halfmann, Y. Kawaoka, C. Piedra-Mora, A. Martinot, S. Kar, H. Andersen, M. G. Lewis, D. H. Barouch

This study shows the SARS-CoV-2 Omicron variant causes less weight loss in hamsters than previous variants, suggesting reduced lower respiratory tract disease severity.

bioRxiv · Jan 2, 2022Microbiology

A Novel CRISPR-Engineered, Stem Cell-Derived Cellular Vaccine

K. Chakraborty, A. Chandrashekar, A. Sidaway, E. Latta, J. Yu, K. McMahan, C. Manickam, K. Kroll, M. Mosher, R. K. Reeves, R. Gam, E. Arthofer, M. Choudhry, D. H. Barouch, T. Henley

This paper describes a CRISPR-engineered cellular vaccine designed to mimic natural immunity, showing robust neutralizing antibody responses and reduced viral load in non-human primates.

bioRxiv · Dec 28, 2021 · PreprintImmunology

mRNA Vaccines Induce Rapid Antibody Responses in Mice

M. Gebre, S. Rauch, N. Roth, J. Gergen, J. Yu, X. Liu, A. Cole, S. Mueller, B. W. Petsch, D. H. Barouch

This study shows mRNA vaccines induce rapid antibody responses in mice by day 5, outperforming DNA, protein, and adenovirus vaccines for SARS-CoV-2 and HIV-1 antigens.

bioRxiv · Nov 1, 2021Microbiology

Ad26.COV2.S Prevents SARS-CoV-2 Induced Pathways of Inflammation and Thrombosis in Hamsters

M. Aid, S. Vidal, C. Piedra-Mora, S. Ducat, C. Chan, S. Bondoc, A. Colarusse, C. Starke, M. Nekorchuk, K. Busman-Sahay, J. Estes, A. Martinot, D. H. Barouch

This study shows that Ad26.COV2.S vaccine prevents SARS-CoV-2-induced inflammation and thrombosis in hamsters by reducing proinflammatory and prothrombotic pathways and restoring gene expression profiles to uninfected levels.

bioRxiv · Sep 30, 2021 · PreprintMicrobiology

A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques

R. R. Cobb, J. Nkolola, P. Gilchuk, A. Chandrashekar, R. V. House, C. G. Earnhart, N. M. Dorsey, S. A. Hopkins, D. M. Snow, R. E. Chen, L. A. VanBlargan, M. Hechenblaickner, B. Hoppe, L. Collins, M. T. Tomic, , J. E. Crowe

This study shows that a combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques and neutralizes variants of concern in vitro.

bioRxiv · Sep 27, 2021 · PreprintImmunology

Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques

J. Yu, N. Collins, N. B. Mercado, K. McMahan, A. Chandrashekar, J. Liu, T. Anioke, A. Chang, V. Giffin, D. Hope, D. Sellers, F. Nampanya, S. Gardner, J. Barrett, H. Wan, , D. H. Barouch

This study evaluates the protective efficacy of oral SARS-CoV-2 delivery in rhesus macaques against respiratory challenges, finding limited immunogenicity and partial protection.

bioRxiv · Sep 13, 2021Microbiology

An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice

F. Borriello, E. Nanishi, H.-S. Seo, T. R. OMeara, M. E. McGrath, Y. Saito, R. E. Haupt, J. Chen, J. Diray-Arce, K. Song, A. Z. Xu, T. M. Caradonna, J. Feldman, B. M. Hauser, A. G. Schmidt, , O. Levy

This study identifies an adjuvanted SARS-CoV-2 RBD nanoparticle that induces neutralizing antibodies and full protection in aged mice.

bioRxiv · Sep 9, 2021 · PreprintImmunology

Subtle immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-functional profiles

P. Kaplonek, D. Cizmeci, S. Fischinger, A.-r. Collier, T. Suscovich, C. Linde, T. Broge, C. Mann, F. Amanat, D. Dayal, J. Rhee, M. de St. Aubin, E. J. Nilles, E. R. Musk, A. S. Menon, , G. Alter

This study compares the Fc-functional antibody profiles of mRNA-1273 and BNT162b2 vaccines in a cohort of hospital staff, finding differences in epitope-specific responses and effector functions.

bioRxiv · Aug 31, 2021 · PreprintImmunology

Optimization of Non-Coding Regions Improves Protective Efficacy of an mRNA SARS-CoV-2 Vaccine in Nonhuman Primates

M. Gebre, S. Rauch, N. Roth, J. Yu, A. Chandrashekar, N. Mercado, X. He, J. Liu, K. McMahan, A. Martinot, T. Giffin, D. Hope, S. Patel, D. Sellers, O. Sanborn, , D. H. Barouch

This study compares two mRNA SARS-CoV-2 vaccines in nonhuman primates, showing that CV2CoV, with optimized non-coding regions, provides better immune responses and protection than CVnCoV.

bioRxiv · Aug 13, 2021 · PreprintImmunology

A modular protein subunit vaccine candidate produced in yeast confers protection against SARS-CoV-2 in non-human primates

N. C. Dalvie, L. H. Tostanoski, S. A. Rodriguez-Aponte, K. Kaur, S. Bajoria, O. Kumru, A. J. Martinot, A. Chandrashekar, K. McMahan, N. B. Mercado, J. Yu, A. Chang, V. M. Giffin, F. Nampanya, S. Patel, , D. H. Barouch

This paper describes a protein subunit vaccine candidate produced in yeast that protects non-human primates against SARS-CoV-2, showing high neutralizing antibody titers and reduced viral loads after challenge.

bioRxiv · Jul 13, 2021 · PreprintImmunology

Protective efficacy of rhesus adenovirus COVID-19 vaccines against mouse-adapted SARS-CoV-2

L. Tostanoski, L. Gralinski, D. Martinez, A. Schaefer, S. Mahrokhian, Z. Li, F. Nampanya, H. Wan, J. Yu, A. Chang, J. Liu, K. McMahan, K. Dinnon, S. R. Leist, R. S. Baric, D. H. Barouch

This study evaluates the protective efficacy of rhesus adenovirus serotype 52 vaccines against a mouse-adapted SARS-CoV-2 strain, showing robust antibody responses and protection against viral replication and disease.

bioRxiv · Jun 14, 2021Microbiology

Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity

E. Nanishi, F. Borriello, T. R. O'Meara, M. E. McGrath, Y. Saito, R. E. Haupt, H.-S. Seo, S. D. van Haren, B. Brook, J. Chen, J. Diray-Arce, S. Doss-Gollin, M. De Leon, K. Chew, M. Menon, , D. J. Dowling

This study evaluates AH:CpG adjuvant's ability to enhance RBD vaccine efficacy in aged mice and human elder cells, showing strong neutralizing antibody responses and cytokine production.

bioRxiv · May 20, 2021Immunology

Natural killer cell immunosuppressive function requires CXCR3-dependent redistribution within lymphoid tissues

A. Ali, L. M. Canaday, H. A. Feldman, H. Cevik, M. T. Moran, S. Rajaram, N. Lakes, J. A. Tuazon, H. Seelamneni, D. Kirshnamurthy, E. Blass, D. H. Barouch, S. N. Waggoner

The paper shows that CXCR3 and type I IFN are critical for NK cell redistribution to T-cell zones, enabling suppression of antiviral T cells during infection.

bioRxiv · May 11, 2021Immunology

SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques

R. Roozendaal, L. Solforosi, D. Stieh, J. Serroyen, R. Straetemans, F. Wegmann, S. K. Rosendahl Huber, J. E. M. van der Lubbe, J. Hendriks, M. le Gars, L. Dekking, D. N. Czapska-Casey, N. Guimera, S. Janssen, S. Tete, , R. Zahn

This study shows that Ad26.COV2.S vaccine provides long-lasting protection in rhesus macaques, predicted by binding and neutralizing antibody levels against SARS-CoV-2.

bioRxiv · Jan 30, 2021Immunology

Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques

X. He, A. Chandrashekar, R. C. Zahn, F. Wegmann, J. Yu, N. B. Mercado, K. McMahan, A. J. Martinot, C. Piedra-Mora, S. Beecy, S. Ducat, R. Chamanza, S. Rosendahl Huber, L. van der Fits, E. N. Borducchi, , D. H. Barouch

This study shows that low doses of Ad26.COV2.S vaccine protect rhesus macaques against SARS-CoV-2 challenge, with higher doses needed for upper respiratory tract protection.

bioRxiv · Jan 27, 2021Immunology

Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing

J. E. M. van der Lubbe, S. K. Rosendahl Huber, A. Vijayan, L. Dekking, E. van Huizen, J. Vreugdenhil, Y. Choi, M. R. M. Baert, K. Feddes-de Boer, A. Izquierdo Gil, M. van Heerden, T. J. Dalebout, S. K. Myeni, M. Kikkert, E. J. Snijder, , F. Wegmann

This study shows that a single dose of Ad26.COV2.S vaccine protects Syrian hamsters from G614 SARS-CoV-2 infection and prevents VAERD even with suboptimal immunity.

bioRxiv · Jan 8, 2021 · PreprintImmunology

A Novel Cell Therapy for COVID-19 and Potential Future Pandemics: Virus Induced Lymphocytes (VIL)

R. Sivapalan, J. Liu, K. Chakraborty, E. Arthofer, M. Choudhry, P. S. Barie, D. H. Barouch, T. Henley

This paper describes a method to generate virus-specific T cells from convalescent patients using artificial antigen presenting cells and rapid expansion, showing their potential as an adoptive cell therapy for COVID-19 and other viral infections.

bioRxiv · Nov 26, 2020Immunology

Immunogenicity and protective efficacy of one- and two-dose regimens of the Ad26.COV2.S COVID-19 vaccine candidate in adult and aged rhesus macaques

L. Solforosi, H. Kuipers, S. K. Rosendahl Huber, J. E. M. van der Lubbe, L. Dekking, D. N. Czapska-Casey, A. Izquierdo Gil, M. Baert, J. Drijver, J. Vaneman, E. van Huizen, Y. Choi, J. Vreugdenhil, S. Kroos, A. H. de Wilde, , R. C. Zahn

This study evaluates one- and two-dose regimens of the Ad26.COV2.S vaccine in rhesus macaques, showing higher antibody responses with two doses and protection against SARS-CoV-2 in aged animals.

bioRxiv · Nov 17, 2020Immunology

Multiplexed proteomics and imaging of resolving and lethal SARS-CoV-2 infection in the lung

M. Kalocsay, Z. Maliga, A. J. Nirmal, R. J. Eisert, G. A. Bradshaw, I. H. Solomon, Y.-A. Chen, R. J. Pelletier, C. A. Jacobson, J. Mintseris, R. F. Padera, A. J. Martinot, D. H. Barouch, S. Santagata, P. Sorger

The paper uses multiplexed proteomics and imaging to compare inflammatory and thrombotic responses in resolving SARS-CoV-2 infection in rhesus macaques and lethal COVID-19 in humans.

bioRxiv · Oct 14, 2020 · PreprintPathology

Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

R. Bos, L. Rutten, J. E. M. van der Lubbe, M. J. G. Bakkers, G. Hardenberg, F. Wegmann, D. Zuijdgeest, A. H. de Wilde, A. Koornneef, A. Verwilligen, D. van Manen, T. Kwaks, R. Vogels, T. J. Dalebout, S. K. Myeni, , H. Schuitemaker

This paper evaluates a prefusion-stabilized SARS-CoV-2 Spike protein vaccine candidate, Ad26.COV2.S, showing potent neutralizing and Th1-polarized immune responses in mice.

bioRxiv · Jul 30, 2020Immunology